Radioactive beads treatment for liver cancer in China
Part of Cancer, Digestive system clinical trials.
This study looks at how patients with liver cancer (HCC) respond to a treatment called SIR-Spheres, which are tiny radioactive beads placed in the liver. It is for people who received this treatment in 2023 or early 2024 and were checked for tumor response within six months after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older
- You must have a confirmed diagnosis of liver cancer (HCC)
- You were treated with SIR-Spheres (yttrium-90) between January 1, 2023, and June 30, 2024
- You had at least one check-up within 6 months after treatment to see how the tumor responded
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment called Y-90 radioembolization (SIRT) for people with liver cancer that is too large to be removed surgically. The treatment delivers tiny radioactive beads directly to the tumor through the liver's blood supply, which may shrink the tumor and improve outcomes.
This study compares two liver-directed treatments—radioactive Yttrium-90 beads (SIRT) and a type of chemo infusion directly into the liver (HAIC)—for people whose liver cancer is advanced enough to need treatment but might still be removable with surgery. The goal is to see which approach can shrink the tumor best before surgery.
This trial tests a treatment that delivers tiny radioactive beads directly to liver tumors through a tube. It is for people with one or a few small liver tumors that cannot be removed with surgery or destroyed with heat or cold. The goal is to shrink or control the tumors with fewer side effects.
This trial tests a treatment that delivers tiny radioactive beads directly to liver tumors to shrink them, which may help patients become eligible for a liver transplant or surgery. It is for people with liver cancer that has not spread outside the liver.
This trial tests a treatment using tiny radioactive beads (TheraSphere) to target and destroy liver tumors in people with early-stage liver cancer. It aims to confirm the safety and effectiveness of a new way to plan the treatment.
This trial is testing a low 'scout' dose of tiny radioactive beads (resin microspheres) given into the liver to treat liver cancer. The goal is to see if this approach is safe and helps patients with certain types of liver cancer that cannot be surgically removed.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.